Larimar Therapeutics, Inc. (LRMR): Price and Financial Metrics
GET POWR RATINGS... FREE!
LRMR Stock Price Chart Interactive Chart >
LRMR Price/Volume Stats
| Current price | $2.64 | 52-week high | $15.49 |
| Prev. close | $2.69 | 52-week low | $2.40 |
| Day low | $2.55 | Volume | 5,800 |
| Day high | $2.72 | Avg. volume | 159,087 |
| 50-day MA | $3.60 | Dividend yield | N/A |
| 200-day MA | $8.73 | Market Cap | 46.75M |
Larimar Therapeutics, Inc. (LRMR) Company Bio
Larimar Therapeutics, Inc. operates as a biotech company. The Company develops and discovers treatments for complex rare diseases such as protein replacement therapy. Larimar Therapeutics serves customers in the State of Pennsylvania.
Latest LRMR News From Around the Web
Below are the latest news stories about Larimar Therapeutics Inc that investors may wish to consider to help them evaluate LRMR as an investment opportunity.
What Made LifeSci Capital Downgrade Larimar Therapeutics’ Stock?In a report released yesterday, Patrick Dolezal from LifeSci Capital downgraded Larimar Therapeutics (LRMR – Research Report) to Hold, with a price target of $3.00. The company's shares closed last Tuesday at $4.01, close to its 52-week low of $2.71. According to TipRanks.com, Dolezal is ranked #7496 out of 7791 analysts. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Larimar Therapeutics with a $8.00 average price target, a 162.3% upside from current levels. In a report released yesterday, William Blair also downgraded the stock to Hold. See Insiders’ Hot Stocks on TipRanks >> Larimar Therapeutics' market cap is currently $148. |
Larimar Therapeutics' stock plunges on FDA decision; could implement cost-cutting measuresThe Food and Drug Administration dealt Larimar Therapeutics a setback when the agency decided to maintain its clinical hold on the Bala Cynwyd biotechnology company's effort to develop a treatment for a rare condition |
Larimar Therapeutics Provides Update on CTI-1601 Clinical ProgramBALA CYNWYD, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has received feedback from the U.S. Food and Drug Administration (FDA) regarding the clinical hold on Larimar’s CTI-1601 program. FDA stated it is maintaining its clinical hold at this time and that additional data is needed to resolve the clinical hold. Larimar is furt |
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare ConferenceBALA CYNWYD, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in virtual 1x1 investor meetings at the Piper Sandler 33rd Annual Healthcare Conference taking place November 29, 2021 through December 2, 2021. About Larimar TherapeuticsLarimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage bio |
LRMR Price Returns
| 1-mo | -23.03% |
| 3-mo | N/A |
| 6-mo | -74.27% |
| 1-year | -82.32% |
| 3-year | -91.67% |
| 5-year | -94.50% |
| YTD | -75.53% |
| 2021 | -49.60% |
| 2020 | 60.74% |
| 2019 | -77.58% |
| 2018 | 7.14% |
| 2017 | 45.28% |
Loading social stream, please wait...